The orphan receptor, bombesin receptor subtype-3(BRS-3) is a G-protein-coupled receptor classified in the bombesin(Bn)receptor family because of its high homology (47-51%) with other members of this family[gastrin-releasing peptide receptor [GRPR] and neuromedin B receptor [NMBR]. There is increasing interest in BRS-3, because primarily from receptor knockout studies, it seems important in energy metabolism, glucose control, insulin secretion, motility and tumor-growth. Pharmacological tools to study the role of BRS-3 in physiology/pathophysiology are limited because the natural ligand is unknown and BRS-3 has low affinity for all naturally-occurring Bn-related peptides. However, a few years ago a synthetic high-affinity agonist [DTyr 6 ,, βAla 11 ,Phe 13 ,Nle 14 ] Bn-(6-14) was described but was nonselective for BRS-3 over other Bn-receptors. Based on this peptide, in various studies a number of putative selective, high-potency hBRS-3 agonists were described, however the results on their selectivity are conflicting in a number of cases. The purpose of the present study was to thoroughly study the pharmacology of four of the most select/potent putative hBRS-3 agonists(#2-4,16a). Each was studied in multiple well-characterized Bn-receptortransfected cells and native Bn-receptor-bearing cells, using binding studies, alterations in cellular signaling (PLC,PKD) and changes in cellular function(growth). Two peptides(#2,#3) had nM affinities/potencies for hBRS-3, peptide #4 had low affinity/potency, and peptide #16a very low (>3000nM). Peptide#3 had the highest selectivity for hBRS-3(100-fold), whereas #2,4 had lower selectivity. Peptide #16a's selectivity could not be determined because of it low affinity/potencies for all hBn-receptors. These results show that peptide#3 is the preferred hBRS-3 agonist for studies at present, although its selectivity of only 100-fold may limit its utility in some cases. This study underscores the importance of full pharmacological characterization of newly reported selective agonists.